Below are the latest news stories about Artelo Biosciences Inc that investors may wish to consider to help them evaluate ARTL as an investment opportunity.
Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK Awarded Mitacs Accelerate GrantLA JOLLA, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2020 and provided a business update.“During the first quarter of fiscal 2021 we received both the Ethics approval and the Clinical Trials Authorization (CTA) in the United Kingdom for the Cancer Appetite Recovery Study (CAReS) for our lead drug candidate, ART27.13, a high-pote... Yahoo | January 14, 2021 |
LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021. A webcast of Artelo's presentation will be available on-demand as of 6:00 a.m. EDT, Monday, January 11, 2021 and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of Artelo's website at https://ir.artelobio.com/.About Artelo BiosciencesArtelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting end... Yahoo | January 5, 2021 |
LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020. “Dr. Reyes’ expert role and track record in taking small molecules and biologics through the development process make him an ideal addition for the next phase of Artelo’s advancement,” commented Connie Matsui, chairperson of Artelo’s Board of Directors. “We are grateful and excited to welcome him to the Board.” Dr. Reyes brings 35 years of experience in biotec... Yahoo | December 2, 2020 |
Artelo Biosciences Inc. (NASDAQ: ARTL ), a San Diego, California, and Dublin, Ireland-based clinical-stage biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system, announced on Monday it received a Clinical Trial Authorization (CTA) in the U.K. for its Cancer Appetite Recovery Study (CAReS). The study will look into ART27.13, a highly potent, peripherally restricted synthetic, dual G protein-coupled receptor agonist believed to target peripheral CB1/CB2 receptors in the endocannabinoid system, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca plc (NASDAQ: AZN ), ART27.13 has been in five Phase 1 clinical studies including over 200 subjects, where it demon... Benzinga | November 19, 2020 |
LA JOLLA, CA / ACCESSWIRE / November 11, 2020 / Artelo Biosciences, Inc. Yahoo | November 11, 2020 |
Loading social stream, please wait...